Dyspnea in patients treated with P2Y12 receptor antagonists: insights from the GReek AntiPlatElet (GRAPE) registry
暂无分享,去创建一个
J. Lekakis | J. Goudevenos | I. Xanthopoulou | D. Alexopoulos | M. Hamilos | N. Barampoutis | I. Kanakakis | G. Sitafidis | S. Deftereos | A. Perperis | M. Vavouranakis | G. Giannopoulos
[1] Ioanna Xanthopoulou,et al. Falta de persistencia con el tratamiento antiplaquetario contemporáneo al año en pacientes con síndrome coronario agudo sometidos a intervención coronaria percutánea , 2016 .
[2] J. Goudevenos,et al. One-year Non-persistence With Contemporary Antiplatelet Therapy in Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention. , 2016, Revista espanola de cardiologia.
[3] Marc P. Bonaca,et al. Long-term Tolerability of Ticagrelor for the Secondary Prevention of Major Adverse Cardiovascular Events: A Secondary Analysis of the PEGASUS-TIMI 54 Trial. , 2016, JAMA cardiology.
[4] J. Goudevenos,et al. Contemporary antiplatelet treatment in acute coronary syndrome patients undergoing percutaneous coronary intervention: 1‐year outcomes from the GReek AntiPlatElet (GRAPE) Registry , 2016, Journal of thrombosis and haemostasis : JTH.
[5] G. Parodi,et al. Dyspnoea management in acute coronary syndrome patients treated with ticagrelor , 2015, European heart journal. Acute cardiovascular care.
[6] M. Effron,et al. One-Year Post-Discharge Resource Utilization and Treatment Patterns of Patients with Acute Coronary Syndrome Managed with Percutaneous Coronary Intervention and Treated with Ticagrelor or Prasugrel , 2015, American Journal of Cardiovascular Drugs.
[7] H. Gurm,et al. Contemporary Use of Ticagrelor in Interventional Practice (from Blue Cross Blue Shield of Michigan Cardiovascular Consortium). , 2015, The American journal of cardiology.
[8] S. Manzano-Fernández,et al. Ticagrelor related dyspnea in patients with acute coronary syndromes: Incidence and implication on ticagrelor withdrawn. , 2015, International journal of cardiology.
[9] Marc P. Bonaca,et al. Long-term use of ticagrelor in patients with prior myocardial infarction. , 2015, The New England journal of medicine.
[10] M. Keltai,et al. Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes and Chronic Obstructive Pulmonary Disease: An Analysis From the Platelet Inhibition and Patient Outcomes (PLATO) Trial , 2015, Journal of the American Heart Association.
[11] A. Vannacci,et al. Ticagrelor-related dyspnea: an underestimated and poorly managed event? , 2015, International journal of cardiology.
[12] P. Dehghani,et al. Southern Saskatchewan Ticagrelor Registry experience , 2014, Patient preference and adherence.
[13] I. Xanthopoulou,et al. Ticagrelor vs prasugrel one-month maintenance therapy: Impact on platelet reactivity and bleeding events , 2014, Thrombosis and Haemostasis.
[14] L. Maillard,et al. Effect of ticagrelor-related dyspnea on compliance with therapy in acute coronary syndrome patients. , 2014, International journal of cardiology.
[15] J. Sidaway,et al. Characterization of the Adenosine Pharmacology of Ticagrelor Reveals Therapeutically Relevant Inhibition of Equilibrative Nucleoside Transporter 1 , 2014, Journal of cardiovascular pharmacology and therapeutics.
[16] C. Stefanadis,et al. Implementation of contemporary oral antiplatelet treatment guidelines in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a report from the GReek AntiPlatelet rEgistry (GRAPE). , 2013, International journal of cardiology.
[17] G. Brandrup-Wognsen,et al. Ticagrelor enhances adenosine-induced coronary vasodilatory responses in humans. , 2013, Journal of the American College of Cardiology.
[18] E. Faioni,et al. Why does ticagrelor induce dyspnea? , 2012, Thrombosis and Haemostasis.
[19] C. Cannon,et al. Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes. , 2011, European heart journal.
[20] C. Cannon,et al. Pulmonary function in patients with acute coronary syndrome treated with ticagrelor or clopidogrel (from the Platelet Inhibition and Patient Outcomes [PLATO] pulmonary function substudy). , 2011, The American journal of cardiology.
[21] Marco Valgimigli,et al. Standardized Bleeding Definitions for Cardiovascular Clinical Trials: A Consensus Report From the Bleeding Academic Research Consortium , 2011, Circulation.
[22] P. Gurbel,et al. Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor, clopidogrel, or placebo in the ONSET/OFFSET study. , 2010, Journal of the American College of Cardiology.
[23] Claes Held,et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. , 2009, The New England journal of medicine.
[24] E. Antman,et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. , 2007, The New England journal of medicine.
[25] C. Cannon,et al. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. , 2007, Journal of the American College of Cardiology.
[26] P. Sandset,et al. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. , 2006, European heart journal.
[27] L. Wallentin,et al. Contemporary use of ticagrelor in patients with acute coronary syndrome: insights from Swedish Web System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies (SWEDEHEART). , 2016, European heart journal. Cardiovascular pharmacotherapy.
[28] C. Stefanadis,et al. In-hospital switching of oral P2Y12 inhibitor treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention: prevalence, predictors and short-term outcome. , 2014, American heart journal.